These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 21110881)

  • 1. Cervical cancer screening in Australia: modelled evaluation of the impact of changing the recommended interval from two to three years.
    Creighton P; Lew JB; Clements M; Smith M; Howard K; Dyer S; Lord S; Canfell K
    BMC Public Health; 2010 Nov; 10():734. PubMed ID: 21110881
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expenditure and resource utilisation for cervical screening in Australia.
    Lew JB; Howard K; Gertig D; Smith M; Clements M; Nickson C; Shi JF; Dyer S; Lord S; Creighton P; Kang YJ; Tan J; Canfell K
    BMC Health Serv Res; 2012 Dec; 12():446. PubMed ID: 23216968
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Primary HPV testing versus cytology-based cervical screening in women in Australia vaccinated for HPV and unvaccinated: effectiveness and economic assessment for the National Cervical Screening Program.
    Lew JB; Simms KT; Smith MA; Hall M; Kang YJ; Xu XM; Caruana M; Velentzis LS; Bessell T; Saville M; Hammond I; Canfell K
    Lancet Public Health; 2017 Feb; 2(2):e96-e107. PubMed ID: 29253402
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Age at last screening and remaining lifetime risk of cervical cancer in older, unvaccinated, HPV-negative women: a modelling study.
    Malagón T; Kulasingam S; Mayrand MH; Ogilvie G; Smith L; Bouchard C; Gotlieb W; Franco EL
    Lancet Oncol; 2018 Dec; 19(12):1569-1578. PubMed ID: 30392810
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The projected timeframe until cervical cancer elimination in Australia: a modelling study.
    Hall MT; Simms KT; Lew JB; Smith MA; Brotherton JM; Saville M; Frazer IH; Canfell K
    Lancet Public Health; 2019 Jan; 4(1):e19-e27. PubMed ID: 30291040
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Benefits, harms and cost-effectiveness of cancer screening in Australia: an overview of modelling estimates.
    Lew JB; Feletto E; Wade S; Caruana M; Kang YJ; Nickson C; Simms KT; Procopio P; Taylor N; Worthington J; Smith D; Canfell K
    Public Health Res Pract; 2019 Jul; 29(2):. PubMed ID: 31384886
    [TBL] [Abstract][Full Text] [Related]  

  • 7. How will transitioning from cytology to HPV testing change the balance between the benefits and harms of cervical cancer screening? Estimates of the impact on cervical cancer, treatment rates and adverse obstetric outcomes in Australia, a high vaccination coverage country.
    Velentzis LS; Caruana M; Simms KT; Lew JB; Shi JF; Saville M; Smith MA; Lord SJ; Tan J; Bateson D; Quinn M; Canfell K
    Int J Cancer; 2017 Dec; 141(12):2410-2422. PubMed ID: 28801947
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Transitioning from cytology-based screening to HPV-based screening at longer intervals: implications for resource use.
    Smith MA; Gertig D; Hall M; Simms K; Lew JB; Malloy M; Saville M; Canfell K
    BMC Health Serv Res; 2016 Apr; 16():147. PubMed ID: 27112193
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cervical cancer prevention in Australia: Planning for the future.
    Saville AM
    Cancer Cytopathol; 2016 Apr; 124(4):235-40. PubMed ID: 26619381
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The impact of a two- versus three-yearly cervical screening interval recommendation on cervical cancer incidence and mortality: an analysis of trends in Australia, New Zealand, and England.
    Simonella L; Canfell K
    Cancer Causes Control; 2013 Sep; 24(9):1727-36. PubMed ID: 23832659
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effectiveness Modelling and Economic Evaluation of Primary HPV Screening for Cervical Cancer Prevention in New Zealand.
    Lew JB; Simms K; Smith M; Lewis H; Neal H; Canfell K
    PLoS One; 2016; 11(5):e0151619. PubMed ID: 27187495
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of scaled up human papillomavirus vaccination and cervical screening and the potential for global elimination of cervical cancer in 181 countries, 2020-99: a modelling study.
    Simms KT; Steinberg J; Caruana M; Smith MA; Lew JB; Soerjomataram I; Castle PE; Bray F; Canfell K
    Lancet Oncol; 2019 Mar; 20(3):394-407. PubMed ID: 30795950
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The cost-effectiveness of cervical screening in Australia: what is the impact of screening at different intervals or over a different age range?
    Anderson R; Haas M; Shanahan M
    Aust N Z J Public Health; 2008 Feb; 32(1):43-52. PubMed ID: 18290913
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cervical cancer in Australia and the United Kingdom: comparison of screening policy and uptake, and cancer incidence and mortality.
    Canfell K; Sitas F; Beral V
    Med J Aust; 2006 Nov; 185(9):482-6. PubMed ID: 17137451
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Decision-analytic modeling to evaluate the long-term effectiveness and cost-effectiveness of HPV-DNA testing in primary cervical cancer screening in Germany.
    Sroczynski G; Schnell-Inderst P; Mühlberger N; Lang K; Aidelsburger P; Wasem J; Mittendorf T; Engel J; Hillemanns P; Petry KU; Krämer A; Siebert U
    GMS Health Technol Assess; 2010 Apr; 6():Doc05. PubMed ID: 21289878
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Projected future impact of HPV vaccination and primary HPV screening on cervical cancer rates from 2017-2035: Example from Australia.
    Hall MT; Simms KT; Lew JB; Smith MA; Saville M; Canfell K
    PLoS One; 2018; 13(2):e0185332. PubMed ID: 29444073
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adapting the Australian system: is an organized screening program feasible in Malaysia?--an overview of cervical cancer screening in both countries.
    Rashid RM; Dahlui M; Mohamed M; Gertig D
    Asian Pac J Cancer Prev; 2013; 14(3):2141-6. PubMed ID: 23679334
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The combined impact of implementing HPV immunisation and primary HPV screening in New Zealand: Transitional and long-term benefits, costs and resource utilisation implications.
    Hall MT; Smith MA; Lew JB; O'Hallahan J; Fentiman G; Neal H; Sage M; Canfell K
    Gynecol Oncol; 2019 Mar; 152(3):472-479. PubMed ID: 30876491
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The recommended interval for cervical cancer screening: Victorian women's attitudes to an extended interval.
    Scalzo K; Mullins R
    Aust N Z J Public Health; 2015 Apr; 39(2):153-6. PubMed ID: 25716065
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The impact of primary HPV screening on the incidence of cervical cancer in New Zealand.
    Cox B; Fitzgerald P; Austin RM; Sneyd MJ
    J Am Soc Cytopathol; 2019; 8(5):258-264. PubMed ID: 31543225
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.